The subcutaneous formulation of mosunetuzumab will require 17 cycles of therapy, without any maintenance, and can be done in outpatient settings.
Tara M. Graff, DO, MS
Advertisement
Articles by Tara M. Graff, DO, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Advises Against BLA for Novel Vaccine Combo/Pembrolizumab in Melanoma
2
Moving Beyond Chemotherapy in Relapsed/Refractory ES-SCLC Treatment
3
TTFields After SRS Prolongs Intracranial Response in Brain Metastatic NSCLC
4
Treatment Decision-Making in Multiple Myeloma at First and Subsequent Relapses
5
